Suppr超能文献

新辅助治疗对不可切除胆囊癌病例进行放射学降期

Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases.

作者信息

Agrawal Sushma, Mohan Lalit, Mourya Chandan, Neyaz Zafar, Saxena Rajan

机构信息

Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India E-mail :

出版信息

Asian Pac J Cancer Prev. 2016;17(4):2137-40. doi: 10.7314/apjcp.2016.17.4.2137.

Abstract

BACKGROUND

Gall bladder cancer (GBC) usually presents as unresectable or metastatic disease. We conducted a feasibility study to evaluate the effect of neoadjuvant therapy (NAT) on radiologic downstaging and resectability in unresectable GBC cases.

MATERIALS AND METHODS

Patients with locally advanced disease were treated with chemoradiotherapy [CTRT] ( external radiotherapy (45Gy) along with weekly concurrent cisplatin 35mg/ m2 and 5-FU 500 mg) and those with positive paraaortic nodes were treated with neoadjuvant chemotherapy [NACT (cisplatin 25mg/m2 and gemcitabine 1gm/m2 day 1 and 8, 3 weekly for 3 cycles). Radiological assessment was according to RECIST criteria by evaluating downstaging of liver involvement and lymphadenopathy into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).

RESULTS

A total of 40 patients were evaluated from January 2012 to December 2014 (CTRT=25, NACT=15). Pretreatment CT scans revealed involvement of hilum (19), liver infiltration (38), duodenum involvement (n=22), colon involvement (n=11), N1 involvement (n=11), N2 disease (n=8), paraaortic LN (n=15), and no lymphadenopathy (n=6). After neoadjuvant therapy, liver involvement showed CR in 11(30%), PR in 4 (10.5%), SD in 15 (39.4%) and lymph node involvement showed CR in 17 (50%), PR in 6 (17.6%), SD in 4 (11.7 %). Six patients (CTRT=2, NACT=4) with 66.6 % and 83% downstaging of liver and lymphnodes respectively underwent extended cholecystectomy. There was 16.6 % and 83.3% rates of histopathological CR of liver and lymph nodes. All resections were R0.

CONCLUSIONS

Neoadjuvant therapy in unresectable gall bladder cancer results in a 15% resectability rate. This approach has a strong potential in achieving R0 and node negative disease. Radiologic downstaging (CR+PR) of liver involvement is 40.5% and lymphadenopathy is 67.5%. Nodal regression could serve as a predictor of response to neoadjuvant therapy.

摘要

背景

胆囊癌(GBC)通常表现为不可切除或转移性疾病。我们开展了一项可行性研究,以评估新辅助治疗(NAT)对不可切除GBC病例的放射学降期和可切除性的影响。

材料与方法

局部晚期疾病患者接受放化疗[CTRT](外照射放疗(45Gy),同时每周顺铂35mg/m²和5-氟尿嘧啶500mg),腹主动脉旁淋巴结阳性患者接受新辅助化疗[NACT(顺铂25mg/m²和吉西他滨1g/m²,第1天和第8天,每3周1次,共3个周期)]。放射学评估根据RECIST标准进行,通过评估肝脏受累和淋巴结病的降期情况分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)。

结果

2012年1月至2014年12月共评估了40例患者(CTRT组25例,NACT组15例)。治疗前CT扫描显示肝门受累(19例)、肝浸润(38例)、十二指肠受累(22例)、结肠受累(11例)、N1受累(11例)、N2期疾病(8例)、腹主动脉旁淋巴结受累(15例)和无淋巴结病(6例)。新辅助治疗后,肝脏受累显示CR 11例(30%)、PR 4例(10.5%)、SD 15例(39.4%),淋巴结受累显示CR 17例(50%)、PR 6例(17.6%)、SD 4例(11.7%)。6例患者(CTRT组2例,NACT组4例)肝脏和淋巴结分别有66.6%和83%的降期,接受了扩大胆囊切除术。肝脏和淋巴结的组织病理学CR率分别为16.6%和83.3%。所有切除均为R0切除。

结论

不可切除胆囊癌的新辅助治疗可使可切除率达到15%。这种方法在实现R0切除和淋巴结阴性疾病方面具有很大潜力。肝脏受累的放射学降期(CR+PR)为40.5%,淋巴结病为67.5%。淋巴结退缩可作为新辅助治疗反应的预测指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验